Opaleye Management Inc. Acquires 264,928 Shares of Lyell Immunopharma, Inc. $LYEL

Opaleye Management Inc. lifted its holdings in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 334.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 344,025 shares of the company’s stock after purchasing an additional 264,928 shares during the period. Opaleye Management Inc.’s holdings in Lyell Immunopharma were worth $4,834,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the business. Velan Capital Investment Management LP increased its holdings in Lyell Immunopharma by 2.9% in the second quarter. Velan Capital Investment Management LP now owns 105,000 shares of the company’s stock valued at $1,475,000 after purchasing an additional 3,000 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Lyell Immunopharma by 7.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 85,423 shares of the company’s stock worth $2,629,000 after buying an additional 5,913 shares during the period. BBR Partners LLC bought a new stake in shares of Lyell Immunopharma in the 4th quarter valued at about $210,000. ExodusPoint Capital Management LP bought a new stake in shares of Lyell Immunopharma in the 4th quarter valued at about $262,000. Finally, Marshall Wace LLP acquired a new stake in shares of Lyell Immunopharma in the second quarter valued at about $94,000. Institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Stock Performance

Shares of LYEL opened at $12.20 on Friday. Lyell Immunopharma, Inc. has a 52-week low of $11.47 and a 52-week high of $45.00. The stock’s 50-day simple moving average is $14.08 and its 200 day simple moving average is $17.31. The stock has a market capitalization of $298.90 million, a price-to-earnings ratio of -0.95 and a beta of -0.04.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($1.92) earnings per share for the quarter, beating the consensus estimate of ($1.94) by $0.02. Lyell Immunopharma had a negative return on equity of 91.62% and a negative net margin of 920,285.25%.The firm had revenue of $0.00 million for the quarter, compared to analysts’ expectations of $0.00 million. On average, research analysts forecast that Lyell Immunopharma, Inc. will post -7.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on LYEL. B. Riley Financial started coverage on Lyell Immunopharma in a research report on Wednesday, July 22nd. They set a “buy” rating and a $44.00 price objective for the company. Citizens Jmp reaffirmed a “market outperform” rating and set a $34.00 price target on shares of Lyell Immunopharma in a research note on Monday, June 15th. Zacks Research raised shares of Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a research note on Monday, May 18th. Citigroup restated a “market outperform” rating on shares of Lyell Immunopharma in a report on Friday, August 14th. Finally, Stifel Nicolaus initiated coverage on shares of Lyell Immunopharma in a report on Thursday, August 6th. They issued a “buy” rating and a $36.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $40.86.

Lyell Immunopharma Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.